Red Yeast Rice Extract Capsules

Red yeast rice is non-glutinous rice, Oryza sativa, solid-state fermented with the mould Monascus purpureus - the Went strain is the classical one - for roughly three to six days, after which the grain carries a bright red core and a reddish-purple exterior. The fermentation produces azaphilone pigments and a family of secondary metabolites called monacolins. The one buyers specify is monacolin K, which is chemically identical to lovastatin: CAS 75330-75-5, C24H36O5, molecular weight 404.54. It exists both as the lactone and as the open hydroxy-acid form, monacolin KA, and a certificate that declares only "total monacolins" is not the same document as one that declares monacolin K - the Went strain typically yields about 0.4% total monacolins in the fermented rice, of which roughly half is monacolin K, so the two figures differ by about a factor of two. Concentrated extracts in trade run from 0.4% up to 5% monacolin K by HPLC. The assay basis, the form reported and the analytical method all belong in the purchase specification in writing. The contaminant that governs this product is citrinin, a nephrotoxic mycotoxin co-produced by Monascus species. The EU maximum for food supplements based on rice fermented with red yeast Monascus purpureus is 100 µg/kg, introduced by Commission Regulation (EU) 2019/1901 and carried into the consolidated contaminants regulation (EU) 2023/915. Thovek tests every lot by HPLC with fluorescence detection or LC-MS/MS and reports the figure rather than a phrase, because "citrinin-free" on a label is marketing and not a specification: a 2021 analysis of thirty-seven marketed products found only one below the EU threshold, and four of the contaminated products were themselves labelled citrinin-free. A 2024 Japanese recall of red yeast rice supplements associated with puberulic acid pushed strain identity and a broader mould-metabolite screen to the front of the specification alongside citrinin, and the specification here reflects that. The commercial reality that should be read before anything else is regulatory, and it differs sharply by market. In the EU, Commission Regulation (EU) 2022/860 amended Annex III to Regulation (EC) No 1925/2006 so that from 22 June 2022 food supplements delivering 3 mg or more of monacolins from red yeast rice per daily portion may not be placed on the market, while products below that threshold carry mandatory warning statements. EFSA's 2018 opinion could not identify an intake of monacolins from red yeast rice it considered safe, and a January 2025 EFSA opinion found the additional data insufficient to change that conclusion. On 4 March 2026 the Commission notified the WTO of a draft regulation (G/SPS/N/EU/923) that would move monacolins from Part B to Part A of Annex III, prohibiting them in foods and food supplements, with a twelve-month stock-disposal period after entry into force; at the time of writing that draft has not been adopted. In the United States the FDA takes the position that red yeast rice with enhanced or added lovastatin cannot be marketed as a dietary supplement and has issued warning letters on that basis. Thovek supplies specification, identity and analysis only, makes no health claim, and expects the buyer to confirm permitted status, permitted level and permitted label wording for each destination before artwork is signed off. The material itself is vegan, vegetarian and gluten-free on an HPMC shell, with no milk, egg, fish, crustacean, soy, peanut or tree nut input.